Clinical Scorecard: Outcomes of COVID-19 in Patients Undergoing Allogeneic Stem Cell Transplantation: A Positive Perspective

At a Glance

Key Highlights

• Among 254 evaluated HSCT patients, 6 were diagnosed with COVID-19 confirmed by PCR.
• Three patients with mild symptoms managed at home with telemedicine; three hospitalized with respiratory support but no ICU admission required.
• All patients recovered fully from COVID-19 with no cases of ARDS, acute cardiac injury, thrombosis, or secondary infections.

Guideline-Based Recommendations

Diagnosis

• Laboratory confirmation of SARS-CoV-2 by RT-PCR assay of nasal and pharyngeal swabs per WHO guidance.
• Use of clinical risk scores to classify COVID-19 severity and guide prognosis and treatment.

Management

• Mild cases managed with home quarantine and telemedicine follow-up.
• Hospitalized patients received antiviral therapy (lopinavir/ritonavir) and hydroxychloroquine per institutional and national guidelines.
• Additional treatments (anakinra, colchicine, enoxaparin) used off-label based on clinical status and persistent fever.
• Empiric antibiotic therapy given for elevated CRP and suspected bacterial co-infections.

Monitoring & Follow-up

• Routine immune reconstitution monitoring including B- and T-cell counts and immunoglobulin levels.
• Close telemedicine and in-person follow-up during and after COVID-19 illness.
• Chest imaging (CT or X-ray) for hospitalized patients to assess pneumonia.

Risks

• Known general population risk factors analyzed but no definitive conclusions due to small HSCT patient sample.
• Persistent immunodeficiency such as B-cell cytopenia or IgA deficit noted in some patients.

Patient & Prescribing Data

Six allogeneic HSCT recipients diagnosed with COVID-19; varying time post-transplant (1 month to >24 months).

Mild cases did not require specific COVID-19 treatment; hospitalized patients treated with lopinavir/ritonavir, hydroxychloroquine, and adjunctive therapies; all patients survived and recovered.

Clinical Best Practices

• Maintain 24/7 hematologist availability for transplant patients with COVID-19 concerns.
• Implement telemedicine for routine follow-up and symptom monitoring to reduce exposure.
• Early testing with nasopharyngeal swabs and prompt home quarantine upon symptom onset.
• Use comprehensive immune monitoring to assess patient risk and recovery status.
• Apply institutional and national guidelines for off-label COVID-19 treatments with informed consent.
• Monitor for and treat bacterial co-infections promptly.

References

• Italian Hematology Alliance on COVID-19
• WHO Laboratory Testing Guidance for COVID-19